naveglitazar
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Non-Insulin-Dependent
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Trial Timeline
— → —
NCT ID
NCT00065312About naveglitazar
naveglitazar is a phase 2 stage product being developed by Eli Lilly for Diabetes Mellitus, Non-Insulin-Dependent. The current trial status is completed. This product is registered under clinical trial identifier NCT00065312. Target conditions include Diabetes Mellitus, Non-Insulin-Dependent.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00065312 | Phase 2 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Non-Insulin-Dependent